The Senator Who Thinks the FDA Is Killing Rare Disease Patients

These aren't obscure cases. They represent some of the most heartbreaking corners of medicine, where patients have almost nothing and the few potential treatments keep getting blocked at the regulatory gate.

A Pattern, Not an Anomaly

Zoom out and the picture gets more troubling. According to testimony from the EveryLife Foundation, the FDA has rejected 23 rare disease therapies since 2025. Many involved reversals of earlier decisions, where the agency shifted its expectations mid-development.

An independent consulting analysis of rare disease decisions from January 2025 through April 2026 found that 7 of 15 rare or orphan drug applications were rejected. The reasons followed a familiar script: trial designs the FDA once seemed willing to accept (single-arm studies, external control groups, biomarker endpoints) were suddenly deemed insufficient.

The rejected drugs span a heartbreaking range of conditions: Hunter syndrome, Friedreich's ataxia, Menkes disease (an ultra-rare pediatric disorder), Barth syndrome, and more. In several cases, the FDA asked companies to run new controlled studies in patient populations so small that recruiting enough participants borders on impossible.

Think of it like asking someone to conduct a statistically rigorous taste test, but only 300 people on Earth have ever tried the food.

The Rare Disease Paradox

Here's what makes this story so complicated: the FDA's overall orphan drug track record is actually strong. Rare disease drugs accounted for roughly 52% of all novel drug approvals in 2024 and 50% in 2025. By the numbers, FDA is approving more rare disease drugs than ever.

But advocates argue the numbers mask a deeper problem. The approvals that go through tend to be for conditions where traditional trial designs work. For ultra-rare diseases (tiny patient populations, no validated endpoints, limited natural history data), the FDA appears to have raised its evidence bar just when these patients need flexibility most.

A physician from Massachusetts General Hospital told the Senate that something has "gone seriously wrong" at the agency, arguing that efficacy requirements built for blockbuster drugs are being applied to conditions affecting a few hundred people. Sen. Kirsten Gillibrand, a Democrat, agreed that the FDA isn't fully using the flexibility Congress already authorized. That kind of bipartisan alignment on a regulatory issue is rare enough to notice.

Coffins at the FDA's Front Door

The patient advocacy community isn't waiting for congressional hearings to make its point. Families affected by MPS (a group of rare metabolic disorders) staged a symbolic funeral outside FDA headquarters, complete with a hearse and coffin, to represent lives they say are being lost while treatments languish in regulatory limbo.

The Cure Sanfilippo Foundation credited months of family advocacy with helping trigger Johnson's investigation. The National Ataxia Foundation is actively collecting patient stories for submission to Senate committees. These groups view Johnson's probe not as a one-off, but as one tool in a multi-front campaign to reshape how the FDA evaluates drugs for tiny patient populations.

Why This Matters Beyond Rare Disease

Johnson's investigation lands at a moment when the FDA is already under extraordinary strain. The agency has cycled through five different directors of its drug center since January. Commissioner Makary is widely expected to be removed. Staff cuts have eliminated roughly 20% of FDA's workforce. Morale is, by most accounts, in the basement.

The user-fee reauthorization process (the "must-pass" legislation that funds FDA's drug review operations) is also ramping up for 2026 negotiations. That gives Congress enormous leverage to attach policy changes to the funding bill: think new requirements for rare disease review flexibility, transparency mandates, or altered approval thresholds.

For biotech companies developing rare disease therapies, the stakes couldn't be higher. Investors already price regulatory risk into these programs. If Congress forces the FDA to codify more flexible standards for ultra-rare conditions, it could unlock billions in development capital. If the probe fizzles into political theater, the chilling effect on rare disease R&D could deepen.

The patients watching this unfold don't care about political theater. They care about whether the drug that might save their child's life gets a fair shot. Right now, they're not convinced it does.

New Drug Prices Just Dropped for the First Time in Years. Don't Celebrate Yet.

Median launch prices for new drugs dropped more than 40% in 2025, falling to $216,000 from over $370,000 the year before. But before you celebrate, the reason has nothing to do with pharma companies charging less.